|
Med-Tech Devices Developed By
Start-ups Stall Life-Threatening Fatalities Like Lung Infection & Neonatal
Respiratory Distress
Novel medical technology devices developed by Indian
start-ups for critical care are proving to be stalling fatalities among
critically ill-patients in the country.
Only recently indigenous start-ups are creating novel
technologies that are directly targeting unmet needs in India. Such technologies
priced at affordable levels have the potential to
transform the healthcare landscape if used at scale. These are only just
beginning to be introduced into the Indian market. So the transformative impact
will only be seen after some years, Siraj Dhanani, Founder and CEO, InnAccel
Technologies told Pharmabiz.
Every medical device developed must solve a serious medical
problem. We developed products for the lower-end medicare setting that do not
have the infrastructure to support hi-end equipment and priced for the mid-tier
Indian healthcare sector, he added.
Our products development teams identified the need in a
critical care setting to prevent fatality. They spent three months in the ICU,
emergency wards, NICUs and rode along with patients in ambulances. Thus came
about VapCare and Saans devices which are CE certified and under USFDA approval
process.
VapCare holds a US, China and India patent and has already
evinced positive customer response from Indian hospitals. This device automates
an oral hygiene procedure currently done manually in a patient under a
ventilator which results in high risk infection and high rate of fatality.
Saans was developed in response to tragic situations of
premature babies rushed to NICUs for ‘Continuous Positive Airway Pressure’ (CPAP),
but succumbed during transport to hospitals. In the absence of CPAP therapy for
a sick baby in transit, Saans is designed to provide breathing support to
neonates in non-NICU settings. The light weight and battery operated device has
completed the field trials. It received a Sparsh grant initiated by BIRAC and
the Millennium Alliance programme by FICCI. Around 90 babies under the study
reported cent percent success and no product failure. Here 24 percent of the
babies were brought in ambulances and 27 percent in auto rickshaws with the
remaining in hired cars or buses along with a qualified medical attendant to
monitor and travel with the patient.
Going by the valuable benefits of both VapCare and Saans, the
company expects a strong government demand. The product is going through USFDA
certification, besides other global validations as InnAccel is keen on exports.
According to Vijayarajan, founder & CTO, InnAccel, the basic
design is completed at the Coeo Labs, the InnAccel subsidiary and the Kaynes
Technology in Mysuru which is armed with certificate for manufacture for these
devices. We are also working on extensive customer demonstrations where
enquiries would be converted into sales going by the potential of the devices.
More details about the company is available at :
http://innaccel.com/
(
http://pharmabiz.com/NewsDetails.aspx?aid=115043&sid=1
)
|
